Gov. Wes Moore made lowering drug costs a key campaign promise, making advocates of the law confident that their greatest ...

It's not too often that pharmaceutical drugs become household names, but that's happening with medicines in the weight loss ...

Dividend investors don't buy shares of companies hoping they will suspend their payouts soon. The longer a corporation ...

Johnson & Johnson’s once-daily oral peptide has bested Bristol Myers Squibb’s reigning oral psoriasis med Sotyktu in a ...

Despite a $3.5 billion impairment charge from Emraclidine's failure, AbbVie's immunology portfolio, led by Skyrizi and Rinvoq ... being studied as a once-daily medicine for use as both a ...

Instead, this investigational medicine mimics the activity of two ... AbbVie's two immunology medicines, Skyrizi and Rinvoq, were the stars of the show, once again. Management continues to expect ...

The arrival of biosimilars like Celltrion's STEQEYMA and Biocon's YESINTEK is shaking up the psoriatic arthritis market, challenging blockbuster biologics with cost-effective alternatives. As ...

The still-growing list reflects recent advances in precision medicine that target specific ... every 12 weeks with a drug like risankizumab [Skyrizi]," she said. "Patients really love that because ...

Skyrizi, Ubrelvy, Vraylar, and Venclexta/Venclyxto. The company also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products, as well as botox ...